Editorial commentary: Closing the loop-a colistin clinical study to confirm dosing recommendations from PK/PD modeling

Clinical Infectious Diseases

Volumn 54, Issue 12, 2012, Pages 1727-1729

  Roberts, Jason A ^a,b   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN;

BLOODSTREAM INFECTION; HUMAN; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT ORGANISM; NOTE; PRESCRIPTION; PRIORITY JOURNAL; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; COLISTIN; CROSS INFECTION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; SEPSIS;

EID: 84861503207     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis311     Document Type: Note

References (18)

1. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96. (Pubitemid 43810035)
2. Oppert M, Engel C, Brunkhorst FM, et al. Acute renal failure in patients with severe sepsis and septic shock-a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant 2008; 23:904-9. (Pubitemid 351767542)
3. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657-68. (Pubitemid 43271379)
4. Lipman J, Udy AA, Roberts JA. Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story. Anaesth Intensive Care 2011; 39:999-1000.
5. Noel GJ, Shah AM, Bagchi P, BAP00248/307 Study Group. Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia. In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: 2008.
6. Gouws D. Healthcare professional communication on the terminated clinical study DORINOS3008 with DORIBAX (doripenem as monohydrate) 500 mg powder for intravenous infusion (AUST R 148517). Sydney, Australia: Janssen Cilag Pty Ltd, 2012:1-3.
7. Li J, Nation RL, Turnidge JD, et al. Colistin: the reemerging antibiotic for multidrugresistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6:589-601.
8. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gramnegative bacteria. Antimicrob Agents Chemother 2009; 53:3430-6.
9. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284-94.
10. Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J. Augmented renal clearance in the intensive care unit: an illustrative case series. Int J Antimicrob Agents 2010; 35:606-8.
11. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.
12. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22:535-43.
13. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50:1953-8. (Pubitemid 43807511)
14. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30:143-51. (Pubitemid 351834728)
15. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45: 781-5. (Pubitemid 32182025)
16. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of oncetwice-and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 2008; 61:636-42. (Pubitemid 351321139)
17. Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010; 30:1279-91.
18. Dalfino L, Puntillo F, Mosca A, et al. High dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012; 54:1720-6.